Professional
Added to YB: 2026-02-05
Pitch date: 2026-02-03
CATX [neutral]
Perspective Therapeutics, Inc.
+8.86%
current return
Author Info
Trickle Research is an independent microcap research firm. Visit the website.
Company Info
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Market Cap
$376.2M
Pitch Price
$5.19
Price Target
15.00 (+165%)
Dividend
N/A
EV/EBITDA
-2.27
P/E
-3.47
EV/Sales
191.00
Sector
Biotechnology
Category
growth
Research Update &Target Decrease - Perspective Therapeutics, Inc.
CATX (price target decrease: 12-24mo price target $15 (prev $22.50). VMT-α-NET Phase 1/2 shows promising toxicity but efficacy skepticism persists. Recent $175M raise at $3.79/share provides trial funding but increases dilution. Sanofi's AlphaMedix discontinuation removes competitor. Radiopharm sector out of favor vs 2024 highs.
Read full article (3 min)